Cue Biopharma, Inc. (CUE)
NASDAQ: CUE · Real-Time Price · USD
0.549
-0.004 (-0.76%)
At close: Dec 5, 2025, 4:00 PM EST
0.572
+0.023 (4.23%)
After-hours: Dec 5, 2025, 7:21 PM EST
Cue Biopharma Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Cue Biopharma stock have an average target of 3.00, with a low estimate of 2.00 and a high estimate of 4.00. The average target predicts an increase of 446.65% from the current stock price of 0.55.
Analyst Consensus: Strong Buy
* Price targets were last updated on Aug 25, 2025.
Analyst Ratings
The average analyst rating for Cue Biopharma stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 3 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| LUCID CAPITAL MARKETS | LUCID CAPITAL MARKETS | Strong Buy Initiates $4 | Strong Buy | Initiates | $4 | +628.86% | Aug 25, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $2 | Buy | Reiterates | $2 | +264.43% | Apr 2, 2025 |
| Stifel | Stifel | Strong Buy Maintains $8 → $4 | Strong Buy | Maintains | $8 → $4 | +628.86% | Aug 20, 2024 |
| JMP Securities | JMP Securities | Buy Maintains $15 → $2 | Buy | Maintains | $15 → $2 | +264.43% | Jul 26, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $8 → $3 | Buy | Maintains | $8 → $3 | +446.65% | Jul 26, 2024 |
Financial Forecast
Revenue This Year
12.68M
from 9.29M
Increased by 36.58%
Revenue Next Year
16.76M
from 12.68M
Increased by 32.10%
EPS This Year
-0.36
from -0.72
EPS Next Year
-0.33
from -0.36
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 18.0M | 24.3M | ||||
| Avg | 12.7M | 16.8M | ||||
| Low | 7.8M | 9.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 93.5% | 91.9% | ||||
| Avg | 36.6% | 32.1% | ||||
| Low | -15.6% | -22.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.32 | -0.19 | |||
| Avg | -0.36 | -0.33 | |||
| Low | -0.40 | -0.47 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.